Medaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
Medaus, Inc. is recalling specific lots of Testosterone Cypionate vials because the company cannot guarantee the product is sterile.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric for potential serious, reversible health consequences.
Plain-English summary
Medaus, Inc. is recalling specific lots of Testosterone Cypionate 20 mg/mL with preservative (benzyl alcohol 2%) in 1 mL and 3 mL vials. The recall is being conducted because the company lacks assurance of the sterility of the affected products.
The affected lots are distributed in the United States, Japan, and New Zealand. The specific lot numbers and expiration dates are: Lot 160302-71 (BUD 08/29/16); Lot 151207-8 (BUD 06/04/16); Lot 160106-34 (BUD 07/04/16); and Lot 160208-22 (BUD 08/16/16).
Consumers and healthcare providers should stop using these products and contact Medaus, Inc. for further instructions or a refund.
The recalled product
- Product
- TESTOSTERONE CYP 20 MG/ML W/PRES (BENZYL ETOH 2%), In a) 1ML Vials and b) 3ML Vials, MEDAUS PHARMACY
- Manufacturer
- Medaus, Inc.
- Category
- Drug — Injectable Steroid
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- a) Lot #: 160302-71
- BUD: 08/29/16. b) Lot #: 151207-8
- BUD: 06/04/16
- Lot #: 160106-34
- BUD: 07/04/16
- Lot #: 160208-22
- BUD: 08/16/16.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 88 recalled by Medaus, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 88 products in this recall →Related recalls
Same manufacturer · Medaus, Inc.
See all →- SevereMedaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Taurine Vials Due to Lack of Sterility Assurance
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Lipo-Injection Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls B-Complex Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls M.I.C. 25/50/50 Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereMedaus Recalls Testosterone Cyp 200 mg/mL Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereTestosterone Cypionate/Propionate Injection Recalled for Sterility Assurance
FDA (Drugs) · 2021-10-06
- SevereNew Vitalis Pharmacy Recalls Testosterone Injection Due to Sterility Concerns
FDA (Drugs) · 2019-12-04
- HighTestosterone Cypionate Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2022-04-06
- SevereRed Mountain Compounding Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2019-11-13
- HighTestosterone Cypionate Injectable Vials Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2022-04-06